Background: NJLCG1402 was a phase I/II trial investigating biweekly nanoparticle albumin-bound paclitaxel (nab-PTX) in patients with advanced non-small cell lung cancer (NSCLC).
Methods: The study included patients aged ≥20 years with previously treated NSCLC. Nab-PTX (100-150 mg/m ) was administered biweekly in a 28-day cycle. The phase I portion was performed to determine the recommended phase II dose of nab-PTX. In the phase II portion, the primary endpoint was the objective response rate. Secondary endpoints were disease control rate, progression-free survival, overall survival, and safety.
Results: A total of 15 patients received biweekly nab-PTX (100-150 mg/m ) and 12 patients in phase II were treated with 150 mg/m . In the phase I portion, 150 mg/m was determined as the recommended dose. Among those treated with 150 mg/m , the objective response rate was 22%, and the median progression-free and overall survival was 3.6 and 11.2 months, respectively. Adverse events grade ≥3 were observed in 39% of patients.
Conclusions: Biweekly nab-PTX monotherapy was well tolerated and exhibited favorable antitumor activity in patients with previously treated NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563146 | PMC |
| http://dx.doi.org/10.1111/1759-7714.14149 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: VG-3927 is a highly potent, selective, brain penetrant, oral small molecule TREM2 agonist that is currently under development for the treatment of Alzheimer's disease (AD). TREM2, a receptor expressed on microglia in the brain is critical to microglial function in health and in disease. Among microglia-associated AD risk genes, partial loss-of-function variants of TREM2 confer 2-3 fold increase in risk for developing AD, motivating efforts to identify pharmacological agonists targeting TREM2 as a therapeutic option.
View Article and Find Full Text PDFCDK2 Allosteric Modulators: The New Route in the Design of New Drugs as Anticancer and Non-hormonal Contraceptives.
Curr Med Chem
January 2025
Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutcihe (STEBICEF) Università di Palermo, Via Archirafi 32, 90123 Palermo.
CDK2 plays a pivotal role in controlling the cell cycle progression in eukaryotes and for this reason, it has been the subject of several studies for suitable inhibitors in the last decades. But more than 30 years of basic research have not generated an inhibitor as marketed drugs. Some inhibitors are to date in early phase clinical development.
View Article and Find Full Text PDFA Spectroscopy Solution for Contactless Conductivity Detection in Capillary Electrophoresis.
Micromachines (Basel)
November 2024
Department of Pharmacognosy, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
This paper introduces a novel contactless single-chip detector that utilizes impedance-to-digital conversion technology to measure impedance in the microfluidic channel or capillary format analytical device. The detector is designed to operate similarly to capacitively coupled contactless conductivity detectors for capillary electrophoresis or chromatography but with the added capability of performing frequency sweeps up to 200 kHz. At each recorded data point, impedance and phase-shift data can be extracted, which can be used to generate impedance versus frequency plots, or phase-shift versus frequency plots.
View Article and Find Full Text PDFLeishmania (Leishmania) amazonensis and Leishmania (Leishmania) infantum sialic acids enhance macrophage infection.
Cell Biol Int
January 2025
Laboratory of Leishmaniasis, Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Leishmaniases affect millions of people around the world, caused by Leishmania parasites. Leishmania are transmitted by female sandflies from Phlebotominae subfamily during their blood meals. In mammals, promastigotes are phagocytosed mainly by macrophages, differentiate into amastigotes and multiply.
View Article and Find Full Text PDFPhase I/II Trial of Perioperative Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal and Gastroesophageal Junction Cancer.
J Surg Oncol
January 2025
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Background And Objectives: Standard treatment of patients with stage II/III esophageal or gastroesophageal junction (E/GEJ) cancer involves neoadjuvant chemoradiation (nCRT), resection, and immunotherapy. Our trial evaluated the addition of perioperative avelumab to standard treatments.
Methods: Patients with resectable E/GEJ cancers received avelumab with nCRT and adjuvant avelumab after resection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!